Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor.

Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor.
复制标题

DOI:
10.3390/biom11081150
复制
发表时间:
2021-08-04
期刊:
影响因子:
5.5
通讯作者:
Petrash JM
Petrash JM
中科院分区:
生物学2区
文献类型:
--
作者:
Gautam D;Pedler MG;Nair DP;Petrash JM

文献摘要

参考文献

被引文献

相似文献

白内障是世界范围内致盲的主要原因。手术摘除白内障是一种安全有效的恢复视力的方法。然而,大量患者后来由于晶状体细胞的再生和随后的视轴退化而出现视力丧失,从而导致视力残疾。这种术后并发症,称为后囊混浊(PCO),发生在高达30%的白内障患者中,并且没有临床证明的药物预防手段。尽管有许多化合物能够预防后囊混浊发生的早期步骤,但目前还没有有效的手段将这种疗法输送到眼睛中,持续适当的时间。为了模拟这一未得到满足的医疗需求的解决方案,我们制作了丙烯基片作为人工晶状体(IOL)的模拟物,在模拟白内障手术后将其放入小鼠晶状体的囊袋中。底物上覆盖着一种亲水性的交联型丙烯酸酯纳米凝胶,旨在洗脱索比尼,一种先前被证明抑制PCO的醛糖还原酶抑制剂。在白内障手术时,将索比尼洗脱装置插入晶状体囊内,可显著防止与后囊混浊发展相关的细胞变化。这一模型表明,白内障抑制剂可以在治疗水平上被输送到术后晶状体囊内。
Cataracts are a leading cause of blindness worldwide. Surgical removal of cataracts is a safe and effective procedure to restore vision. However, a large number of patients later develop vision loss due to regrowth of lens cells and subsequent degradation of the visual axis leading to visual disability. This postsurgical complication, known as posterior capsular opacification (PCO), occurs in up to 30% of cataract patients and has no clinically proven pharmacological means of prevention. Despite the availability of many compounds capable of preventing early steps in PCO development, there is currently no effective means to deliver such therapies into the eye for a suitable duration. To model a solution to this unmet medical need, we fabricated acrylic substrates as intraocular lens (IOL) mimics scaled to place into the capsular bag of the mouse lens following a mock-cataract surgery. Substrates were coated with a hydrophilic crosslinked acrylate nanogel designed to elute Sorbinil, an aldose reductase inhibitor previously shown to suppress PCO. Insertion of the Sorbinil-eluting device into the lens capsule at the time of cataract surgery resulted in substantial prevention of cellular changes associated with PCO development. This model demonstrates that a cataract inhibitor can be delivered into the postsurgical lens capsule at therapeutic levels.
DOI: 10.1016/j.biomaterials.2016.02.038
发表时间: 2016-05-01
期刊: BIOMATERIALS
影响因子: 14
作者:
Lei, Ming;Peng, Zihang;Zhao, Chunshun
通讯作者: Zhao, Chunshun
DOI: 10.1016/s0002-9440(10)63153-7
发表时间: 2004-02-01
影响因子: 6
作者:
Saika, S;Kono-Saika, S;Roberts, AB
通讯作者: Roberts, AB
DOI: 10.1016/s0161-6420(92)31775-0
发表时间: 1992-10-01
期刊: OPHTHALMOLOGY
影响因子: 13.7
作者:
JAVITT, JC;TIELSCH, JM;STEINBERG, EP
通讯作者: STEINBERG, EP
DOI: 10.1007/978-3-319-98788-0_13
发表时间: 2018
影响因子: --
作者:
Chang KC;Petrash JM
通讯作者: Petrash JM
DOI: 10.1016/j.cbi.2021.109495
发表时间: 2021-08-01
影响因子: 5.1
作者:
Hupy ML;Pedler MG;Shieh B;Wang D;Wang XJ;Petrash JM
通讯作者: Petrash JM